FibroGen Inc. (NASDAQ:FGEN) shot up 3.6% on Thursday . The stock traded as high as $18.30 and last traded at $18.27, with a volume of 168,494 shares traded. The stock had previously closed at $17.64.

A number of research analysts have recently commented on the company. Credit Suisse Group AG reaffirmed a “buy” rating on shares of FibroGen in a research note on Tuesday, July 12th. Zacks Investment Research raised FibroGen from a “sell” rating to a “hold” rating in a research note on Tuesday, May 10th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $33.50.

The firm’s market cap is $1.12 billion. The company’s 50-day moving average price is $17.00 and its 200-day moving average price is $18.82.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.11. Equities analysts forecast that FibroGen Inc. will post ($1.02) EPS for the current year.

In related news, CEO Thomas B. Neff sold 27,000 shares of the firm’s stock in a transaction dated Tuesday, May 3rd. The shares were sold at an average price of $17.78, for a total value of $480,060.00. Following the transaction, the chief executive officer now directly owns 3,552,353 shares of the company’s stock, valued at approximately $63,160,836.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider K Peony Yu sold 2,344 shares of the firm’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $17.96, for a total transaction of $42,098.24. Following the completion of the transaction, the insider now directly owns 210,257 shares in the company, valued at $3,776,215.72. The disclosure for this sale can be found here.

Other hedge funds and institutional investors recently modified their holdings of the company. PNC Financial Services Group Inc. raised its position in shares of FibroGen by 8,621.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 35,756 shares of the biopharmaceutical company’s stock worth $1,090,000 after buying an additional 35,346 shares in the last quarter. Rhumbline Advisers raised its position in shares of FibroGen by 8.7% in the fourth quarter. Rhumbline Advisers now owns 45,940 shares of the biopharmaceutical company’s stock worth $1,400,000 after buying an additional 3,675 shares in the last quarter. Nationwide Fund Advisors raised its position in shares of FibroGen by 0.8% in the fourth quarter. Nationwide Fund Advisors now owns 51,597 shares of the biopharmaceutical company’s stock worth $1,572,000 after buying an additional 393 shares in the last quarter. ProShare Advisors LLC bought a new position in shares of FibroGen during the fourth quarter worth $1,715,000. Finally, Swiss National Bank raised its position in shares of FibroGen by 1.8% in the fourth quarter. Swiss National Bank now owns 63,400 shares of the biopharmaceutical company’s stock worth $1,932,000 after buying an additional 1,100 shares in the last quarter.

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.